EUROPEAN COMMISSION APPROVES SUBCUTANEOUS RYBREVANT® (AMIVANTAMAB) CO-FORMULATED WITH ENHANZE® FOR THE TREATMENT OF PATIENTS WITH ADVANCED EGFR-MUTATED NON-SMALL CELL LUNG CANCER

Reuters · 04/07 13:29

Please log in to view news

Recently
Symbol
Price
%Change